BURROUGHS WELLCOME ESTIMATES 3 MIL-PLUS UNTAPPED MARKET FOR OTC ZOVIRAX
This article was originally published in The Tan Sheet
Executive Summary
BURROUGHS WELLCOME ESTIMATES 3 MIL-PLUS UNTAPPED MARKET FOR OTC ZOVIRAX as a treatment for recurrent genital herpes in a May 10 presentation to securities analysts in Baltimore sponsored by Alex. Brown. Burroughs Wellcome VP-Corporate Affairs Larry Wheeler noted that "less than half of the treatable patients, or as many as 3 or 4 mil. individuals...are not currently receiving therapy."